Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study

Wills Eye2 sites in 1 country12 target enrollmentOctober 2012

ConditionsCentral Serous Chorioretinopathy

InterventionsIntravitreal Aflibercept Injection

DrugsIntravitreal Aflibercept Injection

Overview

Phase: Phase 2
Intervention: Intravitreal Aflibercept Injection
Conditions: Central Serous Chorioretinopathy
Sponsor: Wills Eye
Enrollment: 12
Locations: 2
Primary Endpoint: Safety of Intravitreal Aflibercept Injection
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.

Detailed Description

Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study

Registry

clinicaltrials.gov

Start Date

October 2012

End Date

June 2013

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wills Eye

Responsible Party

Principal Investigator

Allen C. Ho, MD

Investigator

Wills Eye

Eligibility Criteria

Inclusion Criteria

•Pre-treatment acuity of 20/40- 20/320
•Macular fluid on optical coherence tomography for greater than 3 months
•Leakage on fluorescein angiography
•Willing and able to comply with clinic visits and study-related procedures
•Provide signed informed consent

Exclusion Criteria

•Treatment for CSCR in the study eye (anti-VEGF, PDT, or laser) within three months prior to study enrollment
•Presence of choroidal neovascularization on enrollment imaging
•Prior vitrectomy in the study eye
•Presence of any substantial ocular disease (other than CSCR) that may compromise vision in the study eye and /or confound interpretation of the data; e.g. substantial cataracts, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, ocular vascular occlusion, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.
•History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
•Uncontrolled glaucoma in the study eye (defined as IOP ≥ 25 mmHg despite treatment with anti-glaucoma medication)
•Active ocular infection or inflammation in the study eye
•Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
•Prior treatment with systemic anti-VEGF agents
•Cerebrovascular accident or myocardial infarction within the preceding 6 months.